Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors

Abstract

EMPA-REG OUTCOME showed a significantly lower rate of hospitalization for heart failure by 35% than placebo [1]. In the CANVAS program [2], there was a significantly lower rate of hospitalization for heart failure in the canagliflozin group (33% relative risk reduction) than placebo. In DECLARETIMI 58, dapagliflozin resulted in a lower rate of hospitalization for heart failure (hazard ratio: 0.73; 95% confidence interval (CI): 0.61 - 0.88) [3].